AptarGroup, Inc. ATR
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +17.96%
- 1 year
- +24.01%
- Open
- 137.00
- Prev close
- 137.20
- Mkt cap
- 9.12B
- Vol
- 882.43K
- Avg vol
- 456.63K
- EPS
- 4.34
- P/E
- 33.15
- Div yield
- 1.46%
More statistics
- Low
- 136.39
- High
- 143.93
- Forward P/E
- 23.30
- Beta
- 0.32
- Short ratio
- 4.15
- Inst. own
- 97.61%
- Dividend
- 2.00
- Ex-div date
- Nov 11, 2026
- Earnings
- Feb 4, 2027
- 50-d avg
- 125.86
- 200-d avg
- 126.95
- 1y target
- 163.25
5D chart
Events in this range
- Oct 29, 2026Earnings: 1.52; estimate 1.47; surprise 3.4%
Signals (141)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 2, 3:30 PM | 10 hours ago |
| SMA: Bullish | Nov 2, 2:45 PM | 10 hours ago |
| SMA: Bearish | Nov 2, 2:40 PM | 10 hours ago |
| SMA: Bullish | Nov 2, 2:35 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 2:10 PM | 11 hours ago |
| MACD: Sell Signal | Nov 2, 2:05 PM | 11 hours ago |
| MACD: Buy Signal | Nov 2, 2:00 PM | 11 hours ago |
| RSI: Overbought | Nov 2, 2:00 PM | 11 hours ago |
| MACD: Sell Signal | Nov 2, 1:50 PM | 11 hours ago |
| MACD: Buy Signal | Nov 2, 1:30 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 1:00 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 1:00 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 12:55 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 12:50 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 12:35 PM | 13 hours ago |
| SMA: Bullish | Nov 2, 12:35 PM | 13 hours ago |
| SMA: Bearish | Nov 2, 12:25 PM | 13 hours ago |
| SMA: Bearish | Nov 2, 12:05 PM | 13 hours ago |
| RSI: Overbought | Nov 2, 11:45 AM | 13 hours ago |
| SMA: Bullish | Nov 2, 11:25 AM | 14 hours ago |
Newest 20 of 141.
News
15 hours ago zacks.com
Investing in AptarGroup (ATR)? Don't Miss Assessing Its International Revenue Trends
Examine AptarGroup's (ATR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
19 hours ago prnewswire.com
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
-- ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation ofcardiac glycogen and cardiac hypertrophy -- -- Data further reinforce scientific rationale for ATR 1072 targeting…
19 hours ago fool.com
Aptar: 3 Key Takeaways for Long-Term Investors
Beauty sales surged 8% but margins stumbled in North America, exposing an execution gap management must close.
2 days ago seekingalpha.com
Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November
Emerson is set to extend its dividend growth streak to 70 years, with a predicted 6.3–8.1% increase driven by a business transformation. EMR's shift to higher-margin Intelligent Devices and Software…
3 days ago seekingalpha.com
Dividend Champion, Contender, And Challenger Highlights: Week November 1
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.
3 days ago seekingalpha.com
AptarGroup, Inc. (ATR) Q3 2026 Earnings Call Transcript
AptarGroup, Inc. ( ATR ) Q3 2026 Earnings Call October 30, 2026 9:00 AM EDT Company Participants Marry Skafidas - Senior Vice President of Investor Relations & Communications Gael Touya - CEO,…
3 days ago marketbeat.com
What AptarGroup (ATR) Said on Its Q3 Earnings Call
AptarGroup NYSE: ATR reported third-quarter 2026 sales growth across its three business segments, while adjusted profitability declined from the prior year as emergency medicine destocking and lower…
3 days ago benzinga.com
AptarGroup Q3 2026 Earnings Call Transcript
AptarGroup (NYSE:ATR) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
4 days ago zacks.com
AptarGroup (ATR) Q3 Earnings and Revenues Beat Estimates
AptarGroup (ATR) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.62 per share a year ago.
-
4 days ago benzinga.com
AptarGroup Raises Quarterly Cash Dividend From $0.48 To $0.50 Per Share
AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Board of Directors declared a quarterly…
4 days ago businesswire.com
Aptar Reports Third Quarter 2026 Results
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Reports Third Quarter 2026 Results.
4 days ago businesswire.com
Aptar Increases Quarterly Dividend to $0.50 Per Share
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Increases Quarterly Dividend to $0.50 Per Share.
5 days ago globenewswire.com
Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program
EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research EMphora™ platform integrates…
-
6 days ago benzinga.com
AptarGroup's Pharma Unit Partners With Stevanato Group To Provide System-Level Data Supporting Earlier Evaluation Of Pre-Filled Syringe Configurations
Focus in on sensitive biologics and other injectable therapies. The work builds on Aptar Pharma's integrated system-level framework, launched in July 2026, and brings complementary expertise together…
-
1 week ago benzinga.com
AptarGroup To Acquire PULMOTREE, A Munich, Germany-based Life Science Company Specializing In Pulmonary Drug Delivery Systems For Targeted Delivery To The Lungs; Terms Not Disclosed
Acquisition is expected to accelerate development and commercialization of Kolibri™ and expand Aptar Pharma’s respiratory drug delivery platformAptar Pharma, a global leader in drug delivery, dosing,…
1 week ago defenseworld.net
AptarGroup, Inc. $ATR Stock Bought by State of Alaska Department of Revenue
State of Alaska Department of Revenue raised its holdings in AptarGroup, Inc. (NYSE: ATR) by 53.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange…
2 weeks ago defenseworld.net
AptarGroup, Inc. (ATR) – What Are Brokerages Saying About This Stock?
Shares of AptarGroup, Inc. (NYSE: ATR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten ratings firms that are currently covering the firm, MarketBeat.com reports.…
-
2 weeks ago benzinga.com
AptarGroup's Aptar Pharma Reveals CE Marking For LuerVax
Aptar Pharma, part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its LuerVax® intranasal…
-
3 weeks ago benzinga.com
UBS Initiates Coverage On AptarGroup with Neutral Rating, Announces Price Target of $135
UBS analyst Anojja Shah initiates coverage on AptarGroup (NYSE:ATR) with a Neutral rating and announces Price Target of $135.
4 weeks ago zacks.com
AptarGroup (ATR) Loses 5.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AptarGroup (ATR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings…
1 month ago zacks.com
3 Packaging Stocks Worth Watching Despite Industry Pressure
Although weak demand and tariffs cloud the Zacks Containers - Paper and Packaging industry's near-term outlook, AVY, ATR and KRT are navigating the challenges well.
-
1 month ago benzinga.com
AptarGroup’s Russian Subsidiary Placed Under Temporary External Administration By Kremlin Decree; Says Aptar Vladimir Represented Less Than 0.6% Of Net Sales And Operating Income As Of Dec 31, 2025
AptarGroup, Inc. (the "Company") takes note of the decree of the President of the Russian Federation, published on September 21, 2026, that places the Company’s Russian subsidiary, OOO Aptar Vladimir…
1 month ago defenseworld.net
AptarGroup, Inc. $ATR Shares Sold by Tidal Investments LLC
Tidal Investments LLC lowered its position in AptarGroup, Inc. (NYSE: ATR) by 24.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.…
1 month ago defenseworld.net
VIRGINIA RETIREMENT SYSTEMS ET Al Buys New Holdings in AptarGroup, Inc. $ATR
VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in AptarGroup, Inc. (NYSE: ATR) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission.…
1 month ago seekingalpha.com
AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Aptar Collaborates With Massachusetts General Hospital To Advance Nose-To-Brain Drug Delivery And Accelerate CNS Pipelines
Goal is to help pharmaceutical innovators evaluate opportunities earlier and accelerate future central nervous system pipelinesAptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing…
1 month ago seekingalpha.com
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
2 months ago prnewswire.com
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell…
2 months ago defenseworld.net
Callan Family Office LLC Makes New Investment in AptarGroup, Inc. $ATR
Callan Family Office LLC acquired a new stake in AptarGroup, Inc. (NYSE: ATR) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange…
-
3 months ago benzinga.com
Wells Fargo Maintains Overweight on AptarGroup, Raises Price Target to $155
Wells Fargo analyst Gabe Hajde maintains AptarGroup (NYSE:ATR) with a Overweight and raises the price target from $145 to $155.
-
3 months ago benzinga.com
AptarGroup Q2 Adj. EPS $1.42 Beats $1.35 Estimate, Sales $1.027B Beat $1.008B Estimate
AptarGroup (NYSE:ATR) reported quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $1.35 by 5.19 percent. This is a 14.46 percent decrease over earnings of $1.66 per…
-
6 months ago benzinga.com
Wells Fargo Maintains Overweight on AptarGroup, Raises Price Target to $145
Wells Fargo analyst Gabe Hajde maintains AptarGroup (NYSE:ATR) with a Overweight and raises the price target from $144 to $145.
6 months ago benzinga.com
Full Transcript: AptarGroup Q1 2026 Earnings Call
Full Transcript: AptarGroup Q1 2026 Earnings Call
-
6 months ago benzinga.com
AptarGroup Q1 Adj. EPS $1.19 Beats $1.15 Estimate, Sales $982.868M Beat $955.283M Estimate
AptarGroup (NYSE:ATR) reported quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $1.15 by 3.48 percent. This is a 0.83 percent decrease over earnings of $1.20 per…
6 months ago benzinga.com
Earnings Scheduled For April 30, 2026
Earnings Scheduled For April 30, 2026
-
7 months ago benzinga.com
Wells Fargo Upgrades AptarGroup to Overweight, Raises Price Target to $144
Wells Fargo analyst Gabe Hajde upgrades AptarGroup (NYSE:ATR) from Equal-Weight to Overweight and raises the price target from $133 to $144.
-
7 months ago benzinga.com
AptarGroup Announces That Its Unidose Powder Nasal Spray System Is Being Utilized In ENA Respiratory's Phase II Clinical Study Of INNA 051
Use of Aptar Pharma's UDS Powder system supports the development of a next‑generation, virus‑agnostic nasal spray being evaluated for its potential to help protect against symptomatic viral…
7 months ago benzinga.com
AptarGroup Hires New CEO
AptarGroup names Gael Touya CEO, signaling continuity as analysts react and stock shows mixed momentum near key levels.
-
7 months ago benzinga.com
AptarGroup Appoints Gael Touya As CEO Effective September 1, 2026
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that Gael Touya, a seasoned global executive with…
-
7 months ago benzinga.com
AptarGroup Says Its Proprietary Nasal Delivery System Is Utilized In LTR Pharma's Phase II Clinical Study Of SPONTAN, Investigational Intranasal Spray Under Development For Treatment Of Erectile Dysfunction
Supporting advancement of complex intranasal therapies through clinical developmentAptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer…
8 months ago benzinga.com
Top 2 Energy Stocks That May Plunge This Quarter
Momentum stocks in the energy sector are currently flashing a warning for investors. The RSI indicator shows overbought conditions for NAT and TEN.
8 months ago benzinga.com
Top 2 Defensive Stocks That May Implode This Month
Top 2 Defensive Stocks That May Implode This Month
8 months ago benzinga.com
Top 2 Consumer Stocks You May Want To Dump This Quarter
Top 2 Consumer Stocks You May Want To Dump This Quarter
8 months ago benzinga.com
Top 2 Utilities Stocks That May Collapse This Month
Top 2 Utilities Stocks That May Collapse This Month
8 months ago benzinga.com
Top 3 Materials Stocks That May Plunge This Month
Top 3 Materials Stocks That May Plunge This Month
-
9 months ago benzinga.com
Earnings Scheduled For February 5, 2026
Earnings Scheduled For February 5, 2026
-
10 months ago benzinga.com
AptarGroup Announces That Its Bidose Liquid Nasal Spray System Liquid Is The Mechanism For Delivering The Newly Approved CARDAMYST
Aptar Group, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the…
1 year ago benzinga.com
Earnings Scheduled For October 30, 2025
Earnings Scheduled For October 30, 2025